Skip to content

Study on clinical efficacy of Compound Foercao Mixture in the treatment of acute exacerbation of chronic obstructive pulmonary disease with phlegm-heat stagnation lung syndrome and related risk factors of acute exacerbation of copd

Study on clinical efficacy of Compound Foercao Mixture in the treatment of acute exacerbation of chronic obstructive pulmonary disease with phlegm-heat stagnation lung syndrome and related risk factors of acute exacerbation of copd

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036710
Enrollment
Unknown
Registered
2020-08-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Sponsors

Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Conform to the diagnostic criteria of Western medicine for acute exacerbation of chronic obstructive pulmonary disease; 2. Conform to the syndrome differentiation standard of TCM (phlegm-heat stagnation and lung syndrome); 3. Patients in group B and Group C were included in the comprehensive assessment of COPD; 4. Patients aged between 40 and 75; 5. Those who can accept the treatment of this protocol, cooperate with the completion of clinical observation, and voluntarily sign the informed consent; 6. Patients who had not used traditional Chinese medicine preparation for relieving cough and resolving phlegm within 48 hours before enrollment.

Exclusion criteria

Exclusion criteria: 1. Patients with pneumonia, bronchial asthma, bronchiectasis, tuberculosis, lung cancer, interstitial lung disease or other lung diseases; 2. Patients with chronic obstructive pulmonary disease at stable stage; 3. Patients with severe primary diseases of cardiovascular and cerebrovascular, liver, kidney and hematopoietic system; 4. Pregnant and lactating women; 5. Allergic constitution or allergic to known ingredients of this drug; 6. Persons with mental or legal disabilities.

Design outcomes

Primary

MeasureTime frame
Lung function;

Countries

China

Contacts

Public ContactJiayu Liu

Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine

602054899@qq.com+86 18301947919

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026